Table 2 Cox regression analysis of CENPF protein expression and clinicopathological covariates with survivals in the Cohort II.
From: USP4-mediated CENPF deubiquitylation regulated tumor metastasis in colorectal cancer
| Â | Disease-free Survival | Overall Survival | ||||||
|---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
HR (95%CI) | p Value | HR (95%CI) | p Value | HR (95%CI) | p Value | HR (95%CI) | p Value | |
CENPF-high vs. CENPF-low | 3.309 (1.393–7.862) | 0.007 | 3.991 (1.635–9.738) | 0.002 | 2.142 (1.034–4.439) | 0.040 | 2.651 (1.225–5.738) | 0.013 |
Age (≥60 vs. < 60) | 1.699 (0.659–4.383) | 0.273 |  |  | 1.886 (0.835–4.262) | 0.127 |  |  |
Sex (male vs. female) | 0.817 (0.339–1.973) | 0.654 |  |  | 1.980 (0.806–4.865) | 0.136 |  |  |
Location (rectum vs colon) | 1.043 (0.574–1.894) | 0.890 |  |  | 1.496 (0.913–2.452) | 0.110 |  |  |
TNM stage (III + IV vs I + II) | 2.021 (1.135–3.596) | 0.017 | 2.544 (1.360–4.758) | 0.003 | 3.566 (2.141–5.940) | <0.001 | 3.751 (2.131–6.600) | <0.001 |
Differentiation grade (poorly vs others) | 1.502 (0.714–3.163) | 0.284 |  |  | 1.619 (0.865–3.032) | 0.132 |  |  |
Adjuvant chemotherapy (yes vs no) | 2.101 (0.770–5.735) | 0.147 |  |  | 1.347 (0.613–2.959) | 0.458 |  |  |
Tumor size (cm) (≥4 vs <4) | 0.436 (0.183–1.039) | 0.061 |  |  | 0.483 (0.231–1.013) | 0.054 | 0.907 (0.395–2.081) | 0.817 |
Serum CEA (ng/ml) (≥5 vs <5) | 2.492 (1.032–6.018) | 0.042 | 1.696 (0.650–4.430) | 0.280 | 1.868 (0.897–3.889) | 0.095 | 1.740 (0.831–3.642) | 0.142 |
Serum CA199 (U/ml) (≥37 vs <37) | 3.268 (1.352–7.895) | 0.009 | 3.239 (1.197–8.763) | 0.021 | 1.706 (0.727–4.000) | 0.219 |  |  |
